Invention Grant
- Patent Title: Substituted triazolo bicyclic compounds as PDE2 inhibitors
-
Application No.: US15579878Application Date: 2016-06-27
-
Publication No.: US10357481B2Publication Date: 2019-07-23
- Inventor: Gregori J. Morriello , Lehua Chang , Ashley Forster , Yili Chen , Michael P. Dwyer , Zack Zhiqiang Guo , Ming Wang , Shimin Xu , Yingjian Bo , Jianmin Fu
- Applicant: MERCK SHARP & DOHME CORP. , Gregori J. Morriello , Lehua Chang , Ashley Forster , Yili Chen , Michael P. Dwyer , Zack Zhiqiang Guo , Ming Wang , Shimin Xu , Yingjian Bo , Jianmin Fu
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Sylvia A. Ayler; John C. Todaro
- Priority: WOPCT/CN2015/083060 20150701
- International Application: PCT/US2016/039478 WO 20160627
- International Announcement: WO2017/003894 WO 20170105
- Main IPC: A61K31/4196
- IPC: A61K31/4196 ; C07D471/04 ; C07D487/04 ; A61P25/28 ; A61P25/22 ; A61P25/18 ; A61P25/16 ; A61P25/06 ; A61K31/52
Abstract:
The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Public/Granted literature
- US20180169072A1 SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS Public/Granted day:2018-06-21
Information query
